Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ultragenyx Pharmaceu
(NQ:
RARE
)
46.69
-0.13 (-0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
543,698
Open
46.91
Bid (Size)
45.30 (1)
Ask (Size)
48.81 (1)
Prev. Close
46.82
Today's Range
46.28 - 47.12
52wk Range
31.52 - 54.98
Shares Outstanding
70,814,462
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
March 18, 2024
Via
Benzinga
Performance
YTD
-3.07%
-3.07%
1 Month
-12.99%
-12.99%
3 Month
-3.27%
-3.27%
6 Month
+32.76%
+32.76%
1 Year
+19.50%
+19.50%
More News
Read More
Ultragenyx to Participate at Investor Conferences in March
February 27, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Recap: Ultragenyx Pharmaceutical Q4 Earnings
February 15, 2024
Via
Benzinga
The Latest Analyst Ratings For Ultragenyx Pharmaceutical
February 15, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
February 15, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Preview: Ultragenyx Pharmaceutical's Earnings
February 14, 2024
Via
Benzinga
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
February 08, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
February 06, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
4 Analysts Have This To Say About Ultragenyx Pharmaceutical
January 19, 2024
Via
Benzinga
Expert Ratings for Ultragenyx Pharmaceutical
December 08, 2023
Via
Benzinga
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
February 05, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
January 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
Via
Investor's Business Daily
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
January 08, 2024
From
Mereo BioPharma Group plc
Via
GlobeNewswire
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
January 07, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
January 04, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
January 03, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
December 28, 2023
Via
Investor's Business Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
December 18, 2023
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.